Evoke Pharma Inc (EVOK) Expected to Announce Earnings of -$0.22 Per Share

Wall Street analysts forecast that Evoke Pharma Inc (NASDAQ:EVOK) will post ($0.22) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Evoke Pharma’s earnings. The lowest EPS estimate is ($0.26) and the highest is ($0.18). Evoke Pharma reported earnings of ($0.18) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 22.2%. The business is scheduled to report its next quarterly earnings report on Wednesday, March 21st.

On average, analysts expect that Evoke Pharma will report full-year earnings of ($1.00) per share for the current fiscal year, with EPS estimates ranging from ($1.03) to ($0.96). For the next fiscal year, analysts anticipate that the firm will post earnings of $0.09 per share, with EPS estimates ranging from ($0.54) to $1.16. Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that follow Evoke Pharma.

A number of research firms have recently weighed in on EVOK. Zacks Investment Research raised shares of Evoke Pharma from a “sell” rating to a “hold” rating in a research report on Tuesday, February 6th. HC Wainwright reissued a “buy” rating and set a $9.00 price target on shares of Evoke Pharma in a research report on Tuesday, October 24th. Northland Securities reissued a “buy” rating and set a $10.00 price target on shares of Evoke Pharma in a research report on Wednesday, October 18th. B. Riley reissued a “buy” rating and set a $10.00 price target on shares of Evoke Pharma in a research report on Wednesday, November 15th. Finally, FBR & Co reissued a “buy” rating and set a $10.00 price target on shares of Evoke Pharma in a research report on Thursday, October 19th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $9.14.

A number of institutional investors and hedge funds have recently made changes to their positions in EVOK. Creative Planning bought a new position in Evoke Pharma during the fourth quarter worth $226,000. B. Riley Financial Inc. bought a new position in Evoke Pharma during the fourth quarter worth $249,000. Deutsche Bank AG bought a new position in Evoke Pharma during the fourth quarter worth $452,000. Vanguard Group Inc. lifted its stake in Evoke Pharma by 15.1% during the second quarter. Vanguard Group Inc. now owns 523,650 shares of the specialty pharmaceutical company’s stock worth $1,341,000 after purchasing an additional 68,544 shares during the last quarter. Finally, Sphera Funds Management LTD. lifted its stake in Evoke Pharma by 34.7% during the fourth quarter. Sphera Funds Management LTD. now owns 769,149 shares of the specialty pharmaceutical company’s stock worth $1,738,000 after purchasing an additional 198,127 shares during the last quarter. Hedge funds and other institutional investors own 14.29% of the company’s stock.

Evoke Pharma (EVOK) traded up $0.03 during mid-day trading on Wednesday, hitting $2.44. 29,700 shares of the stock were exchanged, compared to its average volume of 69,305. Evoke Pharma has a twelve month low of $2.19 and a twelve month high of $4.55. The firm has a market capitalization of $37.15, a P/E ratio of -2.39 and a beta of 1.26.

ILLEGAL ACTIVITY WARNING: “Evoke Pharma Inc (EVOK) Expected to Announce Earnings of -$0.22 Per Share” was first posted by American Banking News and is the property of of American Banking News. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.americanbankingnews.com/2018/02/14/evoke-pharma-inc-evok-expected-to-announce-earnings-of-0-22-per-share.html.

About Evoke Pharma

Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

Get a free copy of the Zacks research report on Evoke Pharma (EVOK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Evoke Pharma (NASDAQ:EVOK)

Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply